ASA: Stroke Survivors Face Twofold Higher Risk for MI One Year After Stroke
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 8, 2024 -- Stroke survivors are nearly twofold more likely to have subsequent myocardial infarction (MI) compared with patients experiencing cervical artery dissection (CAD), according to a study presented at the annual American Stroke Association International Stroke Conference 2024, held from Feb. 7 to 9 in Phoenix.
Lukas Strelecky, from Brown University in Providence, Rhode Island, and colleagues utilized a multistate database to examine MI risk poststroke or post-CAD to estimate cardiovascular complication risk. The analysis included 827,761 patients identified from the State Inpatient Database from New York (2011 to 2017) and Florida (2011 to 2019).
The researchers found that 2.39 percent of all patients had MI within one year, including 1.4 percent of the reference group, 3.4 percent with acute ischemic stroke (AIS), 1.5 percent with CAD, and 1.8 percent of those with concurrent AIS and CAD. Patients with AIS alone and patients with concurrent CAD and AIS had a higher MI risk compared with the reference group (hazard ratio [HR], 4.91; 95 percent confidence interval [CI], 4.63 to 5.21 and HR, 1.67; 95 percent CI, 1.02 to 2.73, respectively). Patients with CAD alone had no elevated risk (HR, 1.17; 95 percent CI, 0.66 to 2.06). Patients with AIS alone still had the highest risk for MI (adjusted HR [aHR], 1.87; 95 percent CI, 1.75 to 1.99), followed by patients with concurrent CAD and AIS (aHR, 1.26; 95 percent CI, 1.05 to 1.5) after adjusting for age, diabetes, heart failure, coronary artery disease, and hyperlipidemia. Patients with CAD had a nonsignificant risk in an adjusted analysis (aHR, 1.142; 95 percent CI, 0.82 to 1.58).
“Before, it was just a guess, but now we know that carotid or vertebral artery dissection not causing a stroke does not raise the risk of a heart attack, and it makes sense that clinicians should focus predominantly on stroke prevention in this subgroup of patients,” coauthor Liqi Shu, M.D., also from Brown University, said in a statement.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-02-09 02:15
Read more
- FDA Approves Lymphir (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- AI Model Has Strong Performance for Identifying Pediatric Eye Disease
- USDA Toughens Rules on Salmonella in Poultry
- 16 Natural Ways to Boost Fertility
- 14 Risk Factors Raise Your Odds for Odds for Dementia
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions